Amaran Biotech

Executive Summary

Amaran Biotech is a Taiwan-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics. Founded in 2010 and employing 200–500 staff, the company provides end-to-end services including process development, aseptic filling, adjuvant production (AB-801, QS-21), and analytical testing. It operates GMP-certified facilities and operates Taiwan’s first automated robotic aseptic filling line, positioning it to support vaccine and biologic developers from early-stage through clinical manufacturing. As a private commercial-stage company, Amaran Biotech serves a growing demand for specialized CDMO services in the Asia-Pacific region, leveraging its technical capabilities and regulatory compliance to attract partnerships with biopharma firms. The company’s strategic focus on adjuvants and aseptic filling differentiates it in the competitive CDMO landscape.

Upcoming Catalysts (preview)

• Q3 2026Expansion of adjuvant production capacity (AB-801/QS-21) to meet growing demand70% success
• Q3 2026New contract wins with vaccine developers for clinical-stage manufacturing60% success
• Q4 2026Regulatory approval or certification for new aseptic filling line80% success